Biomarkers for AD are quantifiable signs that facilitate the detection, diagnosis, and monitoring of disease progression as well as the assessment of therapy responses, including amyloid-beta plaque buildup, tau protein tangles, neurodegeneration, and neuroinflammation. This evidence concerns the gene MAPT and Alzheimer disease.